- Home
- GORV vs IMNN Comparison
GORV vs IMNN Comparison
Compare GORV & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- IMNN
- Stock Information
- Founded
- GORV 1976
- IMNN 1982
- Country
- GORV United States
- IMNN United States
- Employees
- GORV N/A
- IMNN N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- IMNN Biotechnology: Pharmaceutical Preparations
- Sector
- GORV Consumer Discretionary
- IMNN Health Care
- Exchange
- GORV Nasdaq
- IMNN Nasdaq
- Market Cap
- GORV 10.6M
- IMNN 12.1M
- IPO Year
- GORV 2015
- IMNN 1985
- Fundamental
- Price
- GORV $3.06
- IMNN $5.42
- Analyst Decision
- GORV
- IMNN Buy
- Analyst Count
- GORV 0
- IMNN 2
- Target Price
- GORV N/A
- IMNN $182.61
- AVG Volume (30 Days)
- GORV 950.5K
- IMNN 54.7K
- Earning Date
- GORV 08-14-2025
- IMNN 11-06-2025
- Dividend Yield
- GORV N/A
- IMNN N/A
- EPS Growth
- GORV N/A
- IMNN N/A
- EPS
- GORV N/A
- IMNN N/A
- Revenue
- GORV $662,952,000.00
- IMNN N/A
- Revenue This Year
- GORV $15.65
- IMNN N/A
- Revenue Next Year
- GORV $20.54
- IMNN N/A
- P/E Ratio
- GORV N/A
- IMNN N/A
- Revenue Growth
- GORV N/A
- IMNN N/A
- 52 Week Low
- GORV $2.22
- IMNN $4.83
- 52 Week High
- GORV $58.80
- IMNN $41.22
- Technical
- Relative Strength Index (RSI)
- GORV 43.41
- IMNN 48.06
- Support Level
- GORV $2.30
- IMNN N/A
- Resistance Level
- GORV $2.89
- IMNN $5.89
- Average True Range (ATR)
- GORV 0.60
- IMNN 0.30
- MACD
- GORV 0.08
- IMNN -0.15
- Stochastic Oscillator
- GORV 18.67
- IMNN 84.82
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About IMNN Imunon Inc.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).